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Abstract 
Rationale: Since its first implementation nanoparticle-assisted photothermal cancer therapy has 
been studied extensively, although mainly with focus on optimal nanoparticle design. However, 
development of efficient treatment protocols, as well as reliable and early evaluation tools in vivo, are 
needed to push the therapy towards clinical translation. Positron emission tomography (PET) is a 
non-invasive imaging technique that is currently finding extensive use for early evaluation of cancer 
therapies; an approach that has become of increasing interest due to its great potential for 
personalized medicine.  
Methods: In this study, we performed PET imaging to evaluate the treatment response two days 
after nanoparticle-assisted photothermal cancer therapy in tumor-bearing mice. We used three 
different tracers; 2′-deoxy-2′-18F-fluoro-D-glucose (18F-FDG), 3′-deoxy-3′-18F-fluorothymidine 
(18F-FLT), and O-(2’-18F-fluoroethyl)-L-tyrosine (18F-FET) to image and measure treatment induced 
changes in glucose uptake, cell proliferation, and amino acid transport, respectively. After therapy, 
tumor growth was monitored longitudinally until endpoint was reached. 
Results: We found that nanoparticle-assisted photothermal therapy overall inhibited tumor 
growth and prolonged survival. All three PET tracers had a significant decrease in tumor uptake two 
days after therapy and these changes correlated with future tumor growth, with 18F-FDG having the 
most predictive value in this tumor model.  
Conclusion: This study shows that 18F-FDG, 18F-FLT, and 18F-FET are all robust markers for the 
treatment response of photothermal therapy, and demonstrate that PET imaging can be used for 
stratification and optimization of the therapy. Furthermore, having a selection of PET tracers that 
can reliably measure treatment response is highly valuable as the individual tracer might be excluded 
in certain applications where physiological processes limit their contrast to background. 
Key words: Photothermal therapy, nanoparticles, PET imaging, response monitoring 
Introduction 
Photothermal cancer therapy is a treatment 
strategy that utilizes light-to-heat converting 
nanoparticles embedded in the tumor to create local 
hyperthermia and ablation by irradiation of 
near-infrared (NIR) light [1-6]. As the nanoparticles 
can be designed to be biocompatible and the laser 
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employed is in the non-phototoxic NIR region, this 
strategy is thought to be highly target specific with 
minimal adverse effects. With the perspective of 
translating photothermal therapy to clinical settings, 
there is now an increasing need for in vivo evaluation 
of the therapy with the help of companion diagnostics 
that can be used for early prognosis and treatment 
optimization.   
Traditionally, evaluation of anti-cancer 
therapeutics has relied on changes in tumor size and 
burden as readout for therapeutic efficacy [7]. The 
process of tumor shrinkage/growth can, however, be 
fairly slow, and changes can often first be detected 
late after treatment initiation. In addition, tumor size 
may not reflect efficacy of cancer therapy, e.g. as seen 
in pseudoprogression during successful immuno-
therapy. In contrast, positron emission tomography 
(PET) is a non-invasive molecular imaging technique 
that provides information on the biological 
functionality of the tumor based on uptake of a 
radiolabeled tracer. Changes in tracer uptake after 
treatment can be used for early response evaluation 
and to predict treatment outcome, thereby identifying 
responders from non-responders and facilitating 
better management of treatment planning [8]. In 
particular glucose analogue, 2′-deoxy-2′-18F-fluoro-D- 
glucose (18F-FDG), has been established as a robust 
tool, based on the high rate of glucose consumption 
commonly found in cancer cells, for tumor detection, 
diagnosis, early treatment evaluation, and patient 
stratification. 18F-FDG is taken up by cells by the same 
pathway as glucose but gets trapped after 
phosphorylation by hexokinase in its first metabolite 
form, as it cannot undergo further metabolization [9].  
Previously, we have shown that 18F-FDG uptake 
is significantly reduced after photothermal cancer 
therapy in human tumor xenografts in mice and can 
be used as a prognostic marker for the therapeutic 
outcome [10]. Although imaging with 18F-FDG shows 
great promise for early response evaluation of 
photothermal therapy there are biological limitations 
to the use of 18F-FDG that can hamper its specificity. 
For example, biological processes, such as 
inflammation, can change the uptake of 18F-FDG [11, 
12]. When inflammation occurs in response to cancer 
therapy, it can lead to an overestimation in the 
18F-FDG tumor signal due to the increase of activated 
inflammatory cells in the target tissue [13]. Also there 
has to be adequate contrast between target and 
background. This sometimes represents a problem in 
tumors with inherent low glucose uptake or with 
tumors where the adjacent tissues have a naturally 
high glucose turnover, e.g., brain tumors. As a 
consequence 18F-FDG imaging is not applicable for all 
tumor types and is, e.g., in clinic not used routinely 
for imaging of brain tumors and prostate cancer [14, 
15]. Also the robustness of 18F-FDG PET for breast 
cancer is much debated [16, 17]. 
Apart from glucose consumption, cell prolifera-
tion is usually also increased in cancerous tissue and 
hence may be a better marker to image in cases where 
18F-FDG cannot be used reliably. The tracer 
3′-deoxy-3′-18F-fluorothymidine (18F-FLT) is a thymid-
ine analogue that has been successfully used to image 
cell proliferation in vivo [18]. Similar to 18F-FDG, 
18F-FLT is taken up by the cell where after it is 
phosphorylated by thymidine kinase 1 and gets 
trapped intracellularly, thereby visualizing nucleotide 
transport [19, 20]. However, 18F-FLT is not 
incorporated into DNA but is considered a surrogate 
marker of DNA synthesis. For imaging of brain 
tumors, where background uptake of 18F-FDG is high 
and 18F-FLT is less valuable as it does not cross the 
intact blood-brain-barrier, the radiolabelled amino 
acid analogue O-(2’-18F-fluoroethyl)-L-tyrosine (18F- 
FET) has been shown to be a good marker [21, 22]. 
18F-FET is taken up by the cells via the L-type amino 
acid transport system, however, it is neither incorpo-
rated into proteins nor metabolized. Therefore it is not 
trapped intracellularly, and consequently 18F-FET is 
mainly visualizing amino acid transport rates [23].  
All three PET tracers mentioned above have 
previously been used both pre-clinically and clinically 
for cancer imaging and treatment evaluation. 
However, dependent on the mechanism of action 
induced by the treatment as well as tumor type, one 
tracer could be more suitable than the others, and 
selecting the right one could improve the outcome for 
the individual patient. To our knowledge, so far only 
18F-FDG has been used for PET-based imaging and 
treatment evaluation of photothermal cancer therapy 
[10, 24-26]. Therefore, the aim of the study was for the 
first time to examine the performance of 18F-FLT and 
18F-FET PET imaging for treatment response 
evaluation of photothermal cancer therapy in a tumor 
model in mice and compare it to that of 18F-FDG.     
Materials and Methods 
Silica-gold nanoshells 
Silica-gold nanoshells (NS) consisting of a 119 ± 5 
nm diameter silica core surrounded by a 19 nm thick 
gold shell were obtained from NanoComposix, USA 
(overall diameter of 157 ± 9 nm). The size of the parti-
cle was measured using transmission electron micro-
scopy by the supplier. The maximum absorbance was 
measured to be 804 nm in water using a UV-visible 
spectrometer also provided by the supplier.  
Animal model 
All animal studies were approved by the Danish 
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Animal Welfare Council, ministry of Justice. Five 
weeks old female Balb/c mice (Charles River) were 
allowed to acclimatize for one week with access to 
water and chow ad libitum. Mouse colon carcinoma 
cell line (CT26; obtained from ATCC) was cultured in 
RPMI-1640 medium supplemented with 10% fetal 
bovine serum and 1% penicillin-streptomycin at 37 °C 
and 5% CO2. Cells were harvested by trypsinization at 
a confluence of 80-90% and subcutaneous tumors 
were established in the left flank of the animals by 
inoculation of ~ 3x105 CT26 cells resuspended in 100 
μl growth media. The tumor growth was followed by 
caliper measurements and tumor volume calculated 
as ½(length x width2). The animals were grouped in 
three studies representing 18F-FDG, 18F-FLT, and 
18F-FET, and within these three groups, three 
subgroups representing: NS and laser irradiation (NS 
group); saline and laser irradiation (saline group); or 
NS but no laser irradiation (sham group). The number 
of animals in the 18F-FDG study was: n = 7 (NS group), 
n = 6 (saline group), and n = 7 (sham group). The 
number of animals in the 18F-FLT study was: n = 8 (NS 
group), n = 7 (saline group), and n = 6 (sham group). 
The number of animals in the 18F-FET study was: n = 7 
(NS group), n = 7 (saline group), and n = 7 (sham 
group). 
Photothermal Therapy 
Immediately after a baseline PET/CT scan, all 
animals were injected with 190 μl of either 4.9x1010 
NS/ml or saline via the tail vein while being 
anesthetized by breathing sevoflurane. 24 hours after 
intravenous injection of either NS or saline, all 
animals were again anesthetized by breathing 
sevoflurane and placed on an irradiation platform 
with temperature control to maintain their body 
temperature. The tumors in the NS and saline groups 
were then irradiated for 5 minutes with an 807 nm 
diode laser with an intensity of 1.5 W/cm2 (beam 
diameter of ~1 cm). In addition, animals were injected 
subcutaneously with ~70 μl of 0.3 mg/ml of Temgesic 
(1:9 ratio to sterile water) for pain relief every 6-8 
hours for 24 hours after treatment. After treatment, 
the tumor growth was monitored using caliper 
measurements and the animals were euthanized 
when their tumor volume exceeded 1000 mm3. 
 Thermographic temperature measurements 
While being irradiated (or sham treated), the 
surface temperature of all tumors was measured 
using thermographic imaging (FLIR T420). Images 
were recorded every 30 seconds and the maximum 
temperature as a function of time was extracted by 
analysis with FLIR tools software. 
PET/CT 
All animals were PET/CT scanned the day 
before laser treatment (baseline scan) and 2 days after 
treatment (day 2). In addition, they were CT scanned 7 
days after treatment. During the entire procedure, 
animals were anesthetized by breathing sevoflurane 
and their temperature kept stable with either a 
heating pad or lamp. As all animals were treated with 
Temgesic that causes loss of appetite and thereby 
weight loss, they were not fasted before PET scans. 
18F- FDG, 18F-FLT, and 18F-FET were obtained from the 
daily productions for clinical use at Department of 
Nuclear Medicine & PET, Rigshospitalet, Denmark. 
Animals were administered ~10 MBq 18F-FDG or 
18F-FLT via the tail vein 1 hour before the PET scan, or 
~5 MBq 18F-FET via the tail vein 30 minutes before the 
PET scan. In between the 18F-FDG or 18F-FET 
injections and the PET/CT scans, the animals were 
kept anesthetized. Static PET images were acquired 
60-70 min post injection (30-40 min post injection for 
18F-FET) with an energy window of 350-650 KeV and a 
time resolution of 6 ns. CT scans were acquired using 
360 projections, 65 kV, 500 μA and 400 ms. PET 
images were reconstructed using a 3-dimensional 
maximum a posteriori algorithm with CT-based 
attenuation correction. PET and CT images were 
co-registered and analyzed using Inveon software 
(Siemens). The mean percentage of injected dose per 
grams of tissue (%ID/g) in the tumor volume was 
extracted by manually drawing regions of interest on 
the entire tumor.   
Autoradiography and hematoxylin and eosin 
(H&E) staining 
For each tracer, a NS, saline and sham group (n 
=3 in each group) were treated and irradiated 
according to the above described treatment protocol. 
At day 2 after treatment, they were injected with 
tracer via the tail vein while being anesthetized by 
breathing sevoflurane. One hour after injection (or 30 
min for 18F-FET), the animals were euthanized and the 
tumors resected. Tumors were immediately frozen by 
immersion in isopentane and embedded in tissue-tek 
and when it had solidified, the tumors were sectioned 
into ~9 µm slices using a cryostat. The sections were 
exposed on phosphorous films and imaged on a 
Cyclone plus imaging system (Perkin Elmer) for 
visualization of the tracers’ intratumoral distribution. 
Thereafter the sections were dried overnight at room 
temperature and transferred to -80°C for further 
analysis. 
For H&E staining, frozen sections were left to 
equilibrate to room temperature for 30 minutes and 
were subsequently immersed in cold acetone and then 
in HistoClear solution (Chemie Brunschwig) to 
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achieve removal of tissue-tek. The sections were then 
rehydrated through a series of ethanol solutions and 
transferred to running water. Afterwards, they were 
stained with hematoxylin for 3 minutes, rinsed in tap 
water and finally stained with eosin for 1 minute. 
Slides were scanned with an Axio Scanner (Axio scan, 
Carl Zeiss, Germany). 
Statistical analysis 
The temperature elevation measured on the 
surface of the tumor with FLIR camera and the mean 
uptake ratios of the PET tracers were compared with 
one-way ANOVA with Tukeys post–hoc test. Survival 
was based on tumor volumes ≥ 1,000 mm3 (humane 
endpoint), and curves were analyzed using Log-rank 
Mantel-Cox test. The mean and max uptake of PET 
tracers and mean CT volume in different groups were 
compared between time points with a two-way 
ANOVA with Sidak post–hoc test. Statistical analyses 
were performed using GraphPad Prism 6. 
Results 
Treatment response to photothermal therapy 
in vivo using silica-gold nanoparticles as 
photothermal agents 
In this study we used 150 nm in diameter NS as 
the heat-transducing agent, a class of NIR-absorbing 
nanoparticles that has been widely used for 
photothermal therapy in animal studies and has been 
included in a few FDA-approved clinical trials [27-29]. 
We have in previous studies made in-depth 
characterization of the properties and heating 
capabilities of these NS both as single particles and in 
bulk [10, 24]. NS have been shown to accumulate 
passively in tumors upon intravenous administration 
in several different tumor models [10, 30-34] and to 
have good treatment effect in the same murine 
colorectal tumor model as used in this study [6]. 
Further, toxicology studies show no signs of adverse 
effects [35, 36].  
Each animal was scanned with only one of the 
PET tracers so the study consisted of three substudies 
where animals were scanned with either 18F-FDG, 
18F-FLT, or 18F-FET before and after treatment (see the 
experimental timeline in Figure 1A). Within each 
substudy there were three treatment groups receiving 
either: NS and laser irradiation (NS group); saline and 
laser irradiation (saline group); or NS but no laser 
irradiation (sham group). The latter two groups serve 
as control groups for the influence of laser irradiation 
and the NS per se, respectively. 
Approximately two weeks before the study was 
initiated, tumors were established subcutaneously in 
the left flank of female Balb/c mice by inoculation of 
CT26 cells. Two days before photothermal treatment 
the mice were grouped so the mean tumor volume, 
assessed by caliper measurements, was matched for 
all three groups. Furthermore, the mean tumor 
volumes in the groups were also kept consistent 
between the three studies (see Figure 1B).   
 
 
Figure 1. Experimental timeline for the study. (A) The experimental setup was the same for all three PET tracers. (B) Graph shows the tumor volume of each 
individual animal whereas the table shows mean ± standard deviation as well as number of animals in each group.    
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After the baseline PET/CT scan, the animals 
were injected intravenously with either NS or saline. 
The nanoparticles were allowed to accumulate for a 
day, where after the animals were treated for 5 min 
with a 807 nm diode laser covering the tumor region 
and using a laser intensity of 1.5 W/cm2. Figure 2A 
shows the average maximum temperature 
development for all groups during laser irradiation 
measured using a thermographic camera on the 
surface of the tumor. In the NS groups the average 
maximum temperature was 50.6 ± 1.6 °C in the 
18F-FDG study, 49.4 ± 2.0 °C in the 18F-FLT study, and 
52.0 ± 1.5 °C in the 18F-FET study. In comparison, the 
average maximum temperature in the saline groups 
was 43.5 ± 0.4 °C in the 18F-FDG study, 42.3 ± 0.5 °C in 
the 18F-FLT study, and 45.1 ± 0.5 °C in the 18F-FET 
study. The average maximum temperatures in the 
sham groups were all ~31 °C. For all three substudies, 
the maximum temperature reached in the NS group 
after 5 min of irradiation was significantly higher than 
in both the control groups (p ≤ 0.01).  
During the entire study, the tumor growth was 
followed ~3 times a week using caliper 
measurements, and when the tumor volumes reached 
1,000 mm3 the animals were euthanized. The study 
was terminated at day 60 after therapy, and animals 
with no tumor regrowth at this time point were 
considered tumor free. Figure 2B shows that the 
tumor growth overall was inhibited in animals in the 
NS group and for all three studies, at least one animal 
had complete tumor disappearance. In comparison, 
the tumor growth in the two control groups 
progressed in a similar manner. This indicates that 
even though the laser in itself can induce a 
temperature rise of ~ 10 °C, as represented in the 
saline groups, it does not inflict enough tissue damage 
to inhibit tumor growth.  
The survival curves for all three studies are 
shown in Figure 2C. In the 18F-FDG study the median 
survival was 25 days in the NS group, 12 days in the 
saline group, and 11 days in the sham group. In the 
18F-FLT study the median survival was 24 days in the 
NS group, 13 days in the saline group, and 13 days in 
the sham group. And finally, in the 18F-FET study the 
median survival was 22 days in the NS group, 15 days 
in the saline group, and 11 days in the sham group. 
The survival curves for the different treatment groups 
were compared with a Log-rank (Mantel-Cox test) 
with p = 0.0099 in the 18F-FDG study, p = 0.0192 in the 
18F-FLT study, and p < 0.0001 in the 18F-FET study. 
 
 
Figure 2: Evaluation of photothermal therapy. (A) Thermographic real-time measurements of maximum tumor surface temperature during irradiation. (B) Tumor 
growth measured after therapy using a caliper. Data is shown until n ≥ 3. (C) Survival after therapy. In (A) and (B) data shown is mean ± standard error of mean 
(S.E.M). 18F-FDG: n = 7 (NS group), n = 6 (saline group), and n = 7 (sham group). 18F-FLT: n = 8 (NS group), n = 7 (saline group), and n = 6 (sham group). 18F-FET: n 
= 7 (NS group), n = 7 (saline group), and n = 7 (sham group).     
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These results show that in all three studies, 
NS-mediated photothermal therapy inhibited tumor 
growth and increased survival compared to groups 
receiving either only laser irradiation (saline group) or 
NS injections  (sham group). 
PET evaluation of photothermal therapy 
Visual inspection of PET/CT images revealed no 
apparent differences in the baseline tumor uptake 
between treatment groups in the 18F-FDG, 18F-FLT, 
and 18F-FET study (Figure 3). However, for all three 
tracers, a reduction in tumor uptake in the NS treated 
animals was evident between baseline and day 2. This 
decrease was not observed in animals receiving saline 
or sham treatment. 
These observations were confirmed by quantita-
tive analysis of tracer uptake in 3D ROIs manually 
drawn on tumor areas (see Figure 4 and extracted 
values listed in Table 1). For all of the tracers there 
was no significant difference in the mean tumor 
uptake at baseline between the three different 
treatment groups (Figure 4A and Table 1). However, 
the tumor accumulation of 18F-FLT showed a larger 
variation between groups, whereas the mean tumor 
uptake of 18F-FET was slightly lower than for 18F-FDG 
and 18F-FLT. Two days after treatment, the mean 
tumor uptake in the NS treated animals was 
significantly reduced compared to baseline for all 
three tracers (Figure 4A and Table 1). This reduction 
was not seen in sham and saline treated animals.  
 
 
Figure 3.  Representative images of 18F-FDG (left panel), 18F-FLT (middle panel) and 18F-FET (right panel) tumor uptake the day before photothermal therapy 
(baseline) and two days after treatment (day 2). Tumors are marked by white arrows.  
 
 
Figure 4: Tumor uptake of the PET tracers. (A-B) The mean and maximum PET tracer uptake (%ID/g) at baseline and day 2 for all NS, saline and sham treated animals 
in the 18F-FDG (left panel), 18F-FLT (middle panel) and 18F-FET (right panel) studies. Data shown is mean ± S.E.M and **p < 0.01, ***p < 0.001, and ****p < 0.0001. 
18F-FDG: n = 7 (NS group), n = 6 (saline group), and n = 7 (sham group). 18F-FLT: n = 8 (NS group), n = 7 (saline group), and n = 6 (sham group). 18F-FET: n = 7 (NS 
group), n = 7 (saline group), and n = 7 (sham group). 
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The same trend was found for the maximum 
tumor uptake, although the changes in accumulation 
between baseline and day 2 were not as significant 
(see Figure 4B). Given that photothermal therapy can 
induce fairly heterogeneous temperatures throughout 
the tumor, the use of a maximum uptake value, that 
only carries information about tracer accumulation in 
a very small portion of the tumor, is likely to be a less 
robust measure for this type of therapy. Therefore, 
further analysis was based on the mean uptake only. 
Next, we evaluated the mean uptake ratio 
between day 2 and baseline as a measure of treatment 
effect (Figure 5A and Table 1). This was found to be 
significantly lower in all the NS groups compared to 
the control groups for all tracers. To see if this change 
in tumor uptake early after therapy could be used as 
an indicator for treatment outcome we examined the 
linear correlation between the uptake ratio and 
survival (see Figure 5B). 18F-FDG showed the highest 
correlation to survival (r2 =0.62, p = 0.0001), although 
all three tracers correlated significantly (r2 =0.43, p = 
0.0013 and r2 =0.34, p = 0.0057 for 18F-FLT and 18F-FET, 
respectively). 
Finally, as change in tumor growth also is 
commonly used in the clinic to assess treatment effect, 
we evaluated the tumor volume from CT scans 7 days 
after therapy (see Figure 5C). This confirmed 
inhibited tumor growth in the NS groups compared to 
the two control groups that both had significant 
increase in tumor volume at day 7 compared to 
baseline. 
 
Table 1: Quantified PET uptake. The table shows the mean tumor 
uptake on baseline and day 2 and the uptake ratio defined as 
Day2/Baseline. Values are given as mean ± S.E.M. 
  Mean uptake  NS Saline Sham 
18F-FDG Baseline (%ID/g) 8.6 ± 0.4 9.1 ± 0.5 9.1 ± 0.6 
Day 2 (%ID/g) 4.7 ± 1.3 8.4 ± 0.6 9.5 ± 0.3 
Ratio (day 2 /baseline) 0.52 ± 0.14 0.93 ± 0.07 1.06 ± 0.05 
18F-FLT Baseline (%ID/g) 8.9 ± 0.6 10.2 ± 1.4 10.8 ± 1.7 
Day 2 (%ID/g) 3.7 ± 0.6 11.9 ± 1.6 10.8 ± 1.4 
Ratio (day 2 /baseline) 0.41 ± 0.06 1.21 ± 0.14 1.03 ± 0.09 
18F-FET Baseline (%ID/g) 7.4 ± 0.4 7.4 ± 0.5 7.5 ± 0.2 
Day 2 (%ID/g) 3.0 ± 0.8 6.7 ± 0.5 7.7 ± 0.4 
Ratio (day 2 /baseline) 0.41 ± 0.11 0.91 ± 0.06 1.03 ± 0.06 
  
 
 
Figure 5: PET/CT-based response analysis. (A) The relative change in mean uptake (day2/baseline) for all NS, saline and sham treated animals in the 18F-FDG (left 
panel), 18F-FLT (middle panel) and 18F-FET (right panel) studies. (B) The correlation between the relative change in uptake and survival. (C) Tumor volumes derived 
from CT scans at baseline and day 7. Data shown is mean ± S.E.M and *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. 18F-FDG: n = 7 (NS group), n = 6 (saline 
group), and n = 7 (sham group). 18F-FLT: n = 8 (NS group), n = 7 (saline group), and n = 6 (sham group). 18F-FET: n = 7 (NS group), n = 7 (saline group), and n = 7 (sham 
group). 
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Figure 6: Autoradiography and H&E staining.  Tissue sections of tumors from each of the treatment groups. Marked-up line represents the border of the tumor. On 
the left side, the intratumoral distribution of the representative PET tracer is shown and on the right side, the corresponding H&E staining. Each autoradiography 
image is scaled to its minimum and maximum value.  
 
Autoradiography and histological analysis of 
intratumoral tracer uptake 
For all three PET tracers, the intratumoral 
distribution was analyzed by autoradiography two 
days after photothermal therapy in tumors from each 
treatment group. For each tumor, the tracer 
accumulation was compared to hematoxylin and 
eosin (H&E) staining (see Figure 6). In NS-treated 
tumors, highly reduced tracer uptake was found to 
correlate with areas of extensive tumor necrosis. From 
analysis of the tumors in the control groups, it was 
evident that the laser or the NS in itself did not cause 
significant damage to create large areas of necrosis. 
However, as expected for tumors when they reach a 
certain size, a small degree of central necrosis was also 
sometimes observed. 
Discussion 
Photothermal cancer therapy using 
light-absorbing nanoparticles as local heat 
transducers offers high specificity and has been 
shown to be effective in many different cancer models 
in animals, while causing minimal side effects [6, 10, 
30-34]. The selection of nanoparticles that fulfill 
requirements for efficient treatment, e.g., high 
light-to-heat conversion, EPR-suitable sizes, and 
biocompatibility, is vast and a result of the effort that 
has been put into developing nanoparticles since the 
therapy was first introduced [37]. To move the 
development of this therapy forward and towards 
clinical translation, protocols for efficacy assessment 
and optimization are needed. For this, non-invasive 
diagnostic modalities are of great value as they allow 
longitudinal tracking of the outcome of therapy, 
meanwhile providing early treatment evaluation that 
potentially could aid stratifying patients into 
responders and non-responders [10, 38-40] 
Motivated by this, we have in the current study 
investigated the use of PET/CT imaging for early 
evaluation of NS-mediated photothermal therapy in 
mice bearing subcutaneous murine colorectal tumors. 
We used 18F-FDG, 18F-FLT, and 18F-FET that are 
imaging glucose uptake, cell proliferation, and amino 
acid transport, respectively. 18F-FDG is undoubtedly 
the most successfully used PET tracer in cancer 
imaging; however, in some tissues the natural high 
glucose consumption can prevent its use [11]. 
Therefore, we also wanted to investigate the use of 
18F-FLT and 18F-FET as they may have higher 
specificity for applications where 18F-FDG is ruled 
out; or even perform better than 18F-FDG overall. 
Finally, we examined if any of them could be used to 
predict long-term treatment outcome. As the three 
tracers target different cellular pathways, the 
treatment response might differ especially in the 
viable cells in the rim of the ablated area. For example, 
18F-FLT uptake could be affected more than the other 
two tracers by changes leading to cell cycle arrest. 
Also, because cancer treatments often induce an 
inflammatory response, tracers less prone to 
accumulate in inflammatory lesions, such as 18F-FET, 
might have a higher specificity [41].  
On the baseline scans we found that all tracers 
had a fairly high and homogeneous tumor uptake, 
with only 18F-FLT showing slightly higher variations 
than the other two tracers. The benefit of this is that 
the groups can easily be compared and that a 
markedly reduction in uptake after therapy can be a 
robust measure of treatment effect. In all three 
substudies, photothermal therapy resulted in 
inhibited tumor growth and overall prolonged 
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survival compared to control treated animals. We 
found that after photothermal therapy, 18F-FDG was 
on average reduced to 52% of its baseline value in the 
tumors treated with NS and laser irradiation. In 
comparison, 18F-FLT and 18F-FET were both reduced 
to 41% of their baseline value, whereas for all three 
tracers the uptake in the control groups was not 
significantly changed on day 2. Treatment-induced 
inflammation could explain why the reduction in 
18F-FDG was slightly smaller compared to the other 
two tracers. The reduction in uptake in treated areas 
was confirmed by comparing tracer accumulation in 
tissue sections measured by autoradiography and 
H&E staining. It was found that areas of the treated 
tumors with low tracer uptake coincided with 
extensive necrotic regions induced by therapy. 
Overall, the pronounced reductions in tumor 
uptake after treatment of all three tracers verify that 
PET imaging can be used to evaluate the treatment 
response early after therapy. Somewhat surprisingly, 
the observed responses from all three tracers were at 
large similar, suggesting that the major contribution 
in imaging signal stems from the ablated region 
where all cells are necrotic. Moreover, to see if the 
relative change in uptake held information on tumor 
growth following therapy we investigated the 
relationship between the uptake ratio (day 
2/baseline) and survival for all animals in the studies. 
We found that tumors with high reduction in uptake 
at day 2 were also the tumors where the treatment 
effect was best and the animals lived longest. In 
particular 18F-FDG had a strong linear relationship 
between change in uptake and overall survival, while 
the correlation was moderate for 18F-FLT and weak for 
18F-FET. As glucose is essential for energy production, 
more or less all viable cells will have a continuously 
basal uptake of 18F-FDG, whereas 18F-FLT and 18F-FET 
accumulation will be more prone to fluctuations 
dependent on the physiological state of the cells. 
Overall these results suggest that for this application, 
18F-FDG may be a better prognostic marker than 
18F-FLT and 18F-FET.   
In each of the NS-treated groups, there were 
animals with complete tumor regression, however, 
most animals experienced tumor relapse. Although 
this was beyond the scope of this study, we believe 
that the treatment response can be optimized by, e.g., 
exposure of higher laser intensity, multiple laser 
irradiations, or combination therapy for synergistic 
effects. For the purpose of optimizing the therapy, 
PET imaging would be a highly valuable tool where 
the tumor uptake early after therapy could be used to 
determine if the response was as desired or otherwise 
direct an early change to a strategy that could 
improve the patient’s outcome. 
Conclusion 
In this study we found that both 18F-FDG, 
18F-FLT, and 18F-FET can be used for early 
non-invasive evaluation of photothermal cancer 
therapy already two days after treatment. Although 
18F-FDG holds the strongest prognostic information in 
this study, this could vary between tumor models. 
The robustness of all three tracers in terms of 
treatment response suggests that the most 
appropriate tracer can be freely selected without loss 
of information relative to the other PET tracers. In 
conclusion, PET imaging using 18F-FDG, 18F-FLT, or 
18F-FET, all commonly used in a clinical setting, are 
reliable methods for evaluation and optimization of 
nanoparticle-assisted photothermal therapy and 
shows promise for personalizing therapy. 
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